Objective: To locate the organic cation transporter 2 (OCT2) in the cochlea of three different species and to modulate the ototoxicity of cisplatin in the guinea pig by pretreatment with phenformin, having a known affinity for OCT2.
INTRODUCTION
Cisplatin is a platinum-based anticancer drug causing nephro-and ototoxic side effects. 1 It has been shown in a number of studies that cisplatin is toxic primarily to the outer hair cells (OHCs) in the organ of Corti. Stria vascularis and the spiral ganglion cells are also reportedly affected by the drug. 2, 3 After cisplatin administration, OHCs are initially damaged in the base of the cochlea, leading to a high-frequency hearing loss. 4 There is an individual susceptibility to cisplatin ototoxicity and no otoprotective treatments are clinically proven. 1 Nephrotoxic side effects resulting from damage to the proximal tubule cells can be alleviated by prehydration and forced diuresis. 5 It is not known how cisplatin is transported from the systemic circulation to the target cells in the inner ear, but active transport mechanisms are suspected. 6, 7 Organic cation transporters (OCTs) located in kidney and liver are known to be involved in the excretion of drugs from the systemic circulation. 8, 9 Various isoforms of OCTs have specific species-and tissue-distribution patterns. 10, 11 Organic cations, such as the antidiabetic drugs metformin 12, 13 and phenformin 14, 15 and the histamine receptor antagonists cimetidine and ranitidine, 16 are transported by OCTs in the renal endothelial cells.
In previous studies, organic transport protein 2 (OCT2) was found to be involved in cisplatin-induced nephro- 17, 18 and ototoxicity. 6 Organic transport protein 2 has been shown to transport cisplatin to the renal proximal tubule cells, 17, [19] [20] [21] [22] and immunostaining has localized OCT2 to the cochlea of the murine inner ear. 6, 23 Depleted ototoxic and nephrotoxic side effects of cisplatin were demonstrated in OCT2-deficient mice and mice treated with cimetidine. 6, 17 We have studied OCT2 because of its suggested causative involvement in the ototoxic side effect of cisplatin. Organic transport protein 2 is not reported to be a transport protein for cisplatin into cancer cells. 24 Therefore, a protective therapy utilizing transport pathways would not counteract the antitumour effect of cisplatin. In this study, phenformin was chosen as an otoprotector because previous studies have shown a competitive inhibitory effect of OCT2. 14, 25 Hence, the aim of the study was two-fold, namely to locate OCT2 by immunohistochemical means in the rat, guinea pig, and pig cochlea and to establish if pretreatment with phenformin reduces cisplatin-induced ototoxicity in the guinea pig in vivo.
MATERIALS AND METHODS

Animals
Guinea pigs (Duncun-Hartley, Lidk€ opings kaninfarm AB, Sweden) and rats (Sprague-Dawley, Scanbur AB, Sollenuna, Sweden) were housed at the animal facility at Karolinska University Hospital in Uppsala, Sweden, and kept in enrichment cages at a room temperature of 21 C, with a 12-hour light-dark cycle and free access to food and tap water. A pig cochlea (Sus Scrofa) was harvested at the Department of Anesthesia, Uppsala University Hospital. Care and use of the animals reported in this study were approved in accordance with ethical standards (Ethical permits N135/11 and C315/5). For immunohistochemical staining, tissues from four untreated female albino rats, four untreated female albino guinea pigs, and an untreated pig were used. In the in vivo study, 15 female albino guinea pigs (range 261-337 g) were used, anesthetized with an intramuscular injection of ketamine (40 mg/kg) and xylazine (10 mg/kg). The weight of the animals was monitored daily, and they were given a daily subcutaneous injection of 5 ml saline. The end of the experiment was set to 96 hours after cisplatin was given; thereafter, the animals were sacrificed with an overdose of pentobarbiturate and cochlea were harvested.
Immunohistochemistry of the Cochleae of Three Different Species
Parvalbumin is known to exert both a cytoplasmatic and a nuclear immunoreactivity in type I spiral ganglion cells and in hair cells. Costaining with parvalbumin and OCT2 was used to identify inner hair cells (IHCs) and OHCs. 26, 27 Kidney served as positive control for OCT2, as shown in previous studies. 20, 28 The perilymphatic space of rat, guinea pig, and pig cochlea was perfused with 4% paraformaldehyde after decapitation, followed by decalcification. One-half of the kidney was fixed with 4% paraformaldehyde. Rat and guinea pig cochlea and kidney were embedded in paraffin, sectioned 5-mm thick, and mounted. The tissue sections were deparaffinized and boiled for 10 minutes in an antigen unmasking solution (Vector Laboratories, Burlingame, CA). A pig cochlea was embedded in Tissue-Tek (OCT Polysciences, Warrington, PA), rapidly frozen, and sectioned at 8 to 10 mm with a cryostat. 29 The frozen sections were collected into gelatin/chrome alum-coated slides and stored below 270 C prior to immunohistochemistry. All sections were incubated with blocking serum (5% goat serum) for 30 minutes at room temperature. Rabbit antirat organic cation transporter 2 (OCT2) polyclonal antibodies, diluted 1:100 (Alpha Diagnostic International, San Antonio, TX), and mouse antiparvalbumin, diluted 1:250 (Chemicon International, Hants, United Kingdom) were used as primary antibodies. All antibodies were diluted in phosphate-buffered saline (PBS). For negative controls, the primary antibodies were excluded and only PBS was used. One separate slide and one section on each slide were used as a negative control. All sections were incubated overnight with primary antibodies at 4 C. Organic transport protein 2 antibodies were visualized by means of indocarbocyanine Cy3 (red dye) conjugated goat antirabbit antibody, diluted 1:200 (Jackson Immuno Research Laboratories Inc., West Grove, PA). Parvalbumin antibodies were visualized by means of Alexa fluor 488 (green dye) conjugated goat antimouse antibody, diluted 1:400 (Invitrogen, Carlsbad, Cal., USA). The secondary antibodies were applied for 60 minutes at room temperature. All slides were mounted with Vecta Shield mounting medium with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA), and nuclei of all sections were then counterstained with DAPI (blue color). Fluorescent signals were analyzed with a light microscope (Zeiss Axio Scope; Carl Zeiss, Jena, Germany) or with a laser confocal microscope (Nikon TE2000; Nikon Co, Tokyo, Japan).
Modulation of Ototoxicity by OCT Inhibition: An In Vivo Study
Fifteen guinea pigs were used, randomized into two groups. The right internal jugular vein was catheterized for drug administration along the venous flow, that is, against the heart. The study group (n 5 8) were given phenformin 20 mg/kg intravenously (phenformin hydrochloride 7.5 mg/ml; SigmaAldrich, Saint Louis, MO) 30 minutes prior to intravenous administration of cisplatin 8 mg/kg (Platinol 1 mg/ml; BristolMyers Squibb Pharmaceuticals, New York, NY). Control animals (n 5 7) were given only cisplatin 8 mg/kg intravenously. The drugs were administered at a flow rate of 1 ml/minute. The ototoxic side effects of cisplatin were assessed and compared between the two groups. All calculated results were "blind." Ototoxicity was evaluated by measuring the electrophysiological hearing thresholds with auditory brainstem response (ABR) and assessing the morphological loss of IHCs and OHCs. The levels of platinum in cochlear tissue were assessed and compared between the two groups. Tucker-Davis Technologies (Gainesville, FL) equipment was used to measure the electrophysiological hearing thresholds of anesthetized animals. Auditory threshold shifts were determined in the left ear at 6.3 kHz, 12.5 kHz, and 20 kHz and calculated as the difference between thresholds obtained before and 96 hours after drug treatment, expressed as dB change. 30 The temporal bones were immediately removed after the animals were euthanized. For morphological calculation of the loss of IHCs and OHCs, the left cochlea was perfused and fixed in 4% paraformaldehyde. After the bone was removed, the hair cells were labeled with phalloidin (diluted 1:200). Hair cells (scar formations) were counted along the cochlea in a Zeiss fluorescence microscope (Carl Zeiss). The percentage of missing hair cells per mm was calculated. 31 Before cisplatin administration, one 0.25-ml blood sample was aspirated from the left jugular vein of control group animals. After 96 hours, 0.25 ml blood was aspirated from the heart from all animals before euthanization. The right cochlea was used to determine the total platinum content in the tissue. From all cochlea, entire basilar membranes, including the organ of Corti and stria vascularis, were pooled together to form one sample. Inductively coupled plasma mass spectrometry (Analytica AB, Luleå, Sweden) was used for the analytical procedure. 32 
Statistical Evaluation
For descriptive data, median (maximum-minimum) values were used. The Mann-Whitney nonparametric test was used to compare the two independent groups. Differences for which P values were 0.05 or less were deemed statistically significant.
RESULTS
Immunohistochemistry
Positive immunolabeling for OCT2 (red) was seen in endothelial tubular cells from renal tissue (Fig. 1A) . This was found in previous studies and served as a positive control. 20, 28 Intense cytoplasmic immunoreactivity Fig. 2A, C, E) . Type I spiral ganglion cells showed intense staining for OCT2 (Fig. 2B, D, F) . Guinea pig and pig cochlea showed positive cytoplasmic and nuclear immunoreactivity to parvalbumin (green) in the IHCs with the connecting axons. Weak staining was also seen in the three rows of OHCs (Fig 2C and  E) . Double staining with parvalbumin showed no detectable immunoreactivity to OCT2 in the hair cells. Type I spiral ganglion cells showed both nuclear and cytoplasmic immunoreactivity to parvalbumin ( Fig. 2D  and F) .
In Vivo Study
The guinea pigs had electrophysiological hearing thresholds in the normal range before treatment. After the intravenous injections of drugs, two animals in the study group died the day after treatment and were excluded. No weight differences were noted between the two groups over the study period (P > 0.05). Generally, there was considerable individual variability of ototoxicity in both groups following cisplatin treatment (Table  I) . No differences in auditory threshold shifts were seen between the two groups. Morphological evaluation revealed a pronounced loss of OHCs, whereas the IHCs were preserved in both groups. No difference in OHCs loss was seen between the two groups (P > 0.05). The platinum content in cochlear tissues did not differ between the groups (P > 0.05) ( Table I) .
DISCUSSION
Organic cation transporters may play an important part in the influx of cisplatin, a highly cytotoxic drug, to cochlear target cells. Organic cation transporter 2 is one transport protein that has been identified to facilitate cisplatin uptake and thereby intensifies to its ototoxic side effect. Inner ears from three different species were analyzed by immunohistochemistry using confocal microscopy, particularly regarding the cellular distribution of OCT2. Positive immunoreactivity to OCT2 was localized in the supporting cells and in the type I spiral ganglion cells from rat, guinea pig, and pig cochlea. These findings may partly corroborate previous studies and indicate a possible involvement of OCT2 in cisplatin ototoxicity. 6 However, administration of phenformin could not demonstrate any reduction of cisplatin ototoxicity or drug uptake, although earlier experimental studies have shown that cisplatin is transported actively by OCT2. 6, 17, 33 The concept of cisplatin ototoxicity as a consequence of active transport is based mainly on immunohistochemistry and polymerase chain reaction in the murine cochlea. 6 In previous studies, the immunoreactivity to OCT2 was identified in stria vascularis, IHCs, OHCs, and in spiral ganglion cells. 6 Our results localize positive immunostaining of OCT2 in the supporting cells without any expression in the hair cells previously described by More et al. 23 Species differences are less likely to explain the inconsistent findings of the cochlear expression of OCT2. A possible explanation for the discrepancy appears more to be related to differences in immunochemical staining and microscopy techniques. In an effort to improve the resolution, confocal immunofluorescence technique was used in the present study. Furthermore, costaining with parvalbumin was carried out, which made it possible to separate the positive immunoreactivity in the organ of Corti between the hair cells and supporting cells, thereby excluding the presence of OCT2 both in the IHCs and OHCs. No immunoreactivity to OCT2 could be visualized in the vicinity of the cochlear vascular networks of the spiral ligament and stria vascularis. 34, 35 These findings casts doubt as to whether OCT2 is involved in cisplatin transport across the blood-perilymph or intrastrial fluid-blood barriers. Because earlier studies using the mouse model have identified OCT2 expression in the stria vascularis, 6, 23 further studies are needed to clarify the role of OCT2 for the uptake from the systemic circulation.
Nuclear immunolabeling with DAPI confirmed a cytoplasmic immunostaining of OCT2, 6, 23 which is known to have 12 transmembrane domains with intraand extracellular loops. 36 The cytoplasmic staining seen in the present study might be due to the antibody binding to amino acids in the endoplasmic reticulum and Golgi apparatus. The uptake of cisplatin in the cochlea is obligatory for the ototoxic side effects. Our previous findings based on pharmacokinetic studies suggested that the ototoxic effect of cisplatin is related to the drug concentration in the perilymphatic compartments. 32, 37 The findings in this study give no support that OCT2 is primarily involved in the uptake of cisplatin from the systemic circulation but does not exclude an OCT2-mediated transport from deeper compartments of the cochlea to the target cells for cisplatin. The complex processes that take place in cisplatin-induced ototoxicity probably involve several series of events, of which influx of the drug to target cells is the crucial first step. The question arises concerning whether OCT2, by acting in the supporting cells, implies an active uptake of cisplatin at these cellular sites and thus if that could be of major importance for the distribution of the drug to the OHCs. Alternatively, the uptake of cisplatin by the supporting 
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cells could lead to apoptosis in these cells as an early event in the ototoxic process preceding injury of the OHCs. Cisplatin is reported to induce toxic lesions on the supporting cells in the organ of Corti, mainly on the DeitersÇ cells that connect the OHCs to the basal membrane. 38, 39 The supporting cells are important for the bolster and survival of the OHCs. Several ion channels 40 and gap junction proteins such as connexins are located in the supporting cells. 27 They are probably involved in the transport and recycling of the potassium that is released from the hair cells and recycled to the endolymphatic compartment. 41 In this study, distinct positivity for OCT2 was identified in DeitersÇ cells, and immunoreactivity of OCT2 was also seen in the pillar cells that form the tunnel of Corti, as well in HensenÇ s and ClaudiusÇ cells situated more laterally in the organ of Corti. 42 Organic cation transporter 2 immunoreactivity in the type I spiral ganglion cells also confirms a direct uptake of cisplatin by these cells. The spiral ganglion cells connect the hair cells to the central nervous system, and the relatively large type I cells comprise 95% of the spiral ganglion cells. Their peripheral processes are connected to the primary sensory cells, the IHCs. 43 No positive immunoreactivity could be identified in the type II spiral ganglion cells.
Recent studies indicate that several protein transporters are involved in the transport mechanisms of cisplatin. The copper transporter Ctr1 has been studied both in the kidney and in the inner ear in relation to the side effects of cisplatin. It has been identified immunohistochemically in the inner ear. 23 An intratympanic administration of copper sulphate prior to cisplatin injection has been found to prevent hearing loss. 23 Because cancer cells reportedly contain Ctrl, 44, 45 local administration of a competitive binder to Ctr1 is preferred, with the intention of reducing the ototoxic effect while preserving antineoplastic activity. In this study, no reduction of the ototoxic side effects induced by cisplatin could be established in guinea pigs pretreated the potential OCT2 antagonist phenformin. This finding was corroborated by the fact that the concentration of total platinum in cochlear tissue did not differ between the two groups. There are several possible explanations for this finding in various combinations. First, phenformin in the guinea pig may not reach the deeper compartments of the inner ear where OCT2 was found to be localized; thus, the passage of phenformin over the blood-perilymph and intrastrial fluid-blood barrier may be restricted. 46, 47 Second, due to an anticipated risk of metabolic acidosis, only a limited dose of phenformin was given in vivo 48 ; hence, the concentration of phenformin that reached OCT2 in the cochlea might have been too weak for a competitive antagonistic effect. And finally, OCT2 in the guinea pig might not primarily be involved in cisplatin transport to the inner ear structures. One limitation of this study was that we did not evaluate the pharmacokinetics of phenformin in blood and scala tympani perilymph.
CONCLUSION
More knowledge about cisplatin transport into the inner ear compartments is necessary in order to understand the evolution of the toxic process. In this study, OCT2 was identified in the cochlea of rat, guinea pig, and pig. One possible problem in our interpretation, in the light of earlier observation, concerns the localization of OCT2 and possible active transport of cisplatin to the target cells via the intrastrial fluid-blood barrier. In contrast to earlier findings, no OCT2 expression was localized to the stria vascularis. Organic cation transporter 2 was located in the supporting cells and type I spiral ganglion cells. The localization of OCT2 in this study gives no support that this transport protein is involved in the uptake of cisplatin from the vascular networks in the cochlea. Systemically administered phenformin did not alleviate cisplatin-induced ototoxicity, possibly due to restricted passage across the intrastrial fluid blood barrier. This present findings afford new insight into the possible mechanism of active cisplatin uptake by target cells. More studies are necessary, however, to obtain a complete picture of these processes as related to various transcellular transport mechanisms in the ear.
